We thank all of the patients and families involved in this study, as well as the data managers and study personnel from the 8 participating centers for this study in the Dana-Farber Cancer Institute Consortium.
Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia
Version of Record online: 16 JUL 2013
Copyright © 2013 American Cancer Society
Volume 119, Issue 19, pages 3555–3562, 1 October 2013
How to Cite
Lipshultz, S. E., Lipsitz, S. R., Kutok, J. L., Miller, T. L., Colan, S. D., Neuberg, D. S., Stevenson, K. E., Fleming, M. D., Sallan, S. E., Franco, V. I., Henkel, J. M., Asselin, B. L., Athale, U. H., Clavell, L. A., Michon, B., Laverdiere, C., Larsen, E., Kelly, K. M. and Silverman, L. B. (2013), Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer, 119: 3555–3562. doi: 10.1002/cncr.28256
- Issue online: 19 SEP 2013
- Version of Record online: 16 JUL 2013
- Manuscript Accepted: 12 JUN 2013
- Manuscript Revised: 6 JUN 2013
- Manuscript Received: 19 APR 2013
- 7Excess reduction of anthracyclines results in inferior event-free survival in core binding factor acute myeloid leukemia in children: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) [abstract]. Blood. 2012;120:Abstract 409., , , et al.
- 14HFE mutations in idiopathic dilated cardiomyopathy. Med Klin (Munich). 2006;101(suppl 1):135–138., , , et al.
- 22Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr. 2010;23:465–495; quiz 576-577., , , et al.
- 36Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL) [abstract]. J Clin Oncol. 2012;30(suppl): Abstract 9504., , , et al.
- 37The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS) [abstract]. J Clin Oncol. 2012;30(suppl):Abstract 9503., , , et al.
- 38Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children's Oncology Group. J Clin Oncol. 2012;30:2545–2551., , , et al.